Back to search
Myeloid Chimerism
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Myeloid Chimerism trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Myeloid Chimerism trials you may qualify forPrevious studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be we…
Background: Sickle cell disease can often be treated with blood stem cell transplants. But for some people the disease returns. This study will give a second t…
AlloHeme is a chimerism test service that utilizes NGS technology to analyze SNP loci to quantify donor and recipient cells by measuring genomic DNA. Before tra…
Background: Sickle cell disease (SCD) is an inherited disorder of the blood. It can damage a person s organs and cause serious illness and death. A blood stem…
The goal of this clinical research study is to learn if Vidaza (azacitidine) when given to patients with CML after an donor stem cell transplant will increase t…